5,134 trials (keyword fallback)
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Mantle Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants
Preterm Labour
Primary: Uterine Natural Killer Cells In Preterm Labor — 21; 1; 0; 0 participants — p=<0.0002
Extranodal Natural Killer/T-Cell Lymphoma
Primary: Objective Response Rate (ORR) Assessed by IRRC — 46.2 percentage of Participants
Peripheral T Cell Lymphoma · PTCL · Extranodal NK/T-cell Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Acute Myelogenous Leukemia
Primary: Disease-free Survival at 6 Months — 0; 4 participants
Plasma Cell Leukemia · Plasma Cell Myeloma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia With Gene Mutations
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Erythroid Leukemia · Acute Megakaryoblastic Leukemia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities (DLT) — 2; 1; 0; 0 Participants
Non-Hodgkin Lymphoma · Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Best Overall Response Rate of Pembrolizumab in Participants With Relapsed/Refractory Gray-zone Lymphomas (GZL) and Extra-nodal Diffuse Large B-cell Lymphomas (DLBCL)…
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Effect of Drugs
Primary: Objective Response Rate (ORR) Before First PD — 60.7 Percentage of Participants
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg